Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis

Shaival H. Davé, Jeremy S. Tilstra, Katsuyoshi Matsuoka, Fengling Li, Richard A. DeMarco, Donna Beer-Stolz, Antonia R. Sepulveda, Mitchell P. Fink, Michael T. Lotze, Scott E. Plevy

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Signals from stressed cells and the enteric microbiota activate macrophages and dendritic cells and mediate intestinal inflammation. HMGB1 serves as an immunogenic stimuli causing release of inflammatory cytokines by myeloid cells. Ethyl pyruvate inhibits secretion of HMGB1 and improves survival in models of endotoxemia and hemorrhagic shock. We reasoned that ethyl pyruvate may be protective in colitis, which involves similar inflammatory pathways. In IL-10-/- mice with established chronic colitis, ethyl pyruvate administration ameliorated colitis and reduced intestinal cytokine production. IL-10-/- mice demonstrated increased intestinal HMGB1 expression and decreased expression of RAGE compared with wild-type mice. Fecal HMGB1 levels were decreased in ethyl pyruvate-treated mice. Furthermore, ethyl pyruvate induced HO-1 expression in intestinal tissue. In TNBS-induced colitis, intrarectal administration of ethyl pyruvate resulted in amelioration of colitis and reduced intestinal cytokine production. In LPS-activated murine macrophages, ethyl pyruvate decreased expression of IL-12 p40 and NO production but did not affect IL-10 levels. Ethyl pyruvate did not inhibit nuclear translocation of NF-κB family members but attenuated NF-κB DNA binding. Additionally, ethyl pyruvate induced HO-1 mRNA and protein expression and HO-1 promoter activation. Moreover, ethyl pyruvate prevented nuclear-to-cytoplasmic translocation of HMGB1. In conclusion, the HMGB1/RAGE pathway has pathophysiologic and diagnostic significance in experimental colitis. Ethyl pyruvate and other strategies to inhibit HMGB1 release and function represent promising interventions in chronic inflammatory diseases.

Original languageEnglish
Pages (from-to)633-643
Number of pages11
JournalJournal of Leukocyte Biology
Volume86
Issue number3
DOIs
Publication statusPublished - 2009 Sep 1

Fingerprint

HMGB1 Protein
Colitis
Interleukin-10
Cytokines
ethyl pyruvate
Macrophages
Endotoxemia
Hemorrhagic Shock
Microbiota
Myeloid Cells
Interleukin-12
Dendritic Cells
Chronic Disease

Keywords

  • Inflammation
  • Inflammatory bowel disease
  • Innate immunity

ASJC Scopus subject areas

  • Cell Biology
  • Immunology

Cite this

Davé, S. H., Tilstra, J. S., Matsuoka, K., Li, F., DeMarco, R. A., Beer-Stolz, D., ... Plevy, S. E. (2009). Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of Leukocyte Biology, 86(3), 633-643. https://doi.org/10.1189/jlb.1008662

Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. / Davé, Shaival H.; Tilstra, Jeremy S.; Matsuoka, Katsuyoshi; Li, Fengling; DeMarco, Richard A.; Beer-Stolz, Donna; Sepulveda, Antonia R.; Fink, Mitchell P.; Lotze, Michael T.; Plevy, Scott E.

In: Journal of Leukocyte Biology, Vol. 86, No. 3, 01.09.2009, p. 633-643.

Research output: Contribution to journalArticle

Davé, SH, Tilstra, JS, Matsuoka, K, Li, F, DeMarco, RA, Beer-Stolz, D, Sepulveda, AR, Fink, MP, Lotze, MT & Plevy, SE 2009, 'Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis', Journal of Leukocyte Biology, vol. 86, no. 3, pp. 633-643. https://doi.org/10.1189/jlb.1008662
Davé SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of Leukocyte Biology. 2009 Sep 1;86(3):633-643. https://doi.org/10.1189/jlb.1008662
Davé, Shaival H. ; Tilstra, Jeremy S. ; Matsuoka, Katsuyoshi ; Li, Fengling ; DeMarco, Richard A. ; Beer-Stolz, Donna ; Sepulveda, Antonia R. ; Fink, Mitchell P. ; Lotze, Michael T. ; Plevy, Scott E. / Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. In: Journal of Leukocyte Biology. 2009 ; Vol. 86, No. 3. pp. 633-643.
@article{4f6f8a270d244aa782a0244e48e30ce3,
title = "Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis",
abstract = "Signals from stressed cells and the enteric microbiota activate macrophages and dendritic cells and mediate intestinal inflammation. HMGB1 serves as an immunogenic stimuli causing release of inflammatory cytokines by myeloid cells. Ethyl pyruvate inhibits secretion of HMGB1 and improves survival in models of endotoxemia and hemorrhagic shock. We reasoned that ethyl pyruvate may be protective in colitis, which involves similar inflammatory pathways. In IL-10-/- mice with established chronic colitis, ethyl pyruvate administration ameliorated colitis and reduced intestinal cytokine production. IL-10-/- mice demonstrated increased intestinal HMGB1 expression and decreased expression of RAGE compared with wild-type mice. Fecal HMGB1 levels were decreased in ethyl pyruvate-treated mice. Furthermore, ethyl pyruvate induced HO-1 expression in intestinal tissue. In TNBS-induced colitis, intrarectal administration of ethyl pyruvate resulted in amelioration of colitis and reduced intestinal cytokine production. In LPS-activated murine macrophages, ethyl pyruvate decreased expression of IL-12 p40 and NO production but did not affect IL-10 levels. Ethyl pyruvate did not inhibit nuclear translocation of NF-κB family members but attenuated NF-κB DNA binding. Additionally, ethyl pyruvate induced HO-1 mRNA and protein expression and HO-1 promoter activation. Moreover, ethyl pyruvate prevented nuclear-to-cytoplasmic translocation of HMGB1. In conclusion, the HMGB1/RAGE pathway has pathophysiologic and diagnostic significance in experimental colitis. Ethyl pyruvate and other strategies to inhibit HMGB1 release and function represent promising interventions in chronic inflammatory diseases.",
keywords = "Inflammation, Inflammatory bowel disease, Innate immunity",
author = "Dav{\'e}, {Shaival H.} and Tilstra, {Jeremy S.} and Katsuyoshi Matsuoka and Fengling Li and DeMarco, {Richard A.} and Donna Beer-Stolz and Sepulveda, {Antonia R.} and Fink, {Mitchell P.} and Lotze, {Michael T.} and Plevy, {Scott E.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1189/jlb.1008662",
language = "English",
volume = "86",
pages = "633--643",
journal = "Journal of Leukocyte Biology",
issn = "0741-5400",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis

AU - Davé, Shaival H.

AU - Tilstra, Jeremy S.

AU - Matsuoka, Katsuyoshi

AU - Li, Fengling

AU - DeMarco, Richard A.

AU - Beer-Stolz, Donna

AU - Sepulveda, Antonia R.

AU - Fink, Mitchell P.

AU - Lotze, Michael T.

AU - Plevy, Scott E.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Signals from stressed cells and the enteric microbiota activate macrophages and dendritic cells and mediate intestinal inflammation. HMGB1 serves as an immunogenic stimuli causing release of inflammatory cytokines by myeloid cells. Ethyl pyruvate inhibits secretion of HMGB1 and improves survival in models of endotoxemia and hemorrhagic shock. We reasoned that ethyl pyruvate may be protective in colitis, which involves similar inflammatory pathways. In IL-10-/- mice with established chronic colitis, ethyl pyruvate administration ameliorated colitis and reduced intestinal cytokine production. IL-10-/- mice demonstrated increased intestinal HMGB1 expression and decreased expression of RAGE compared with wild-type mice. Fecal HMGB1 levels were decreased in ethyl pyruvate-treated mice. Furthermore, ethyl pyruvate induced HO-1 expression in intestinal tissue. In TNBS-induced colitis, intrarectal administration of ethyl pyruvate resulted in amelioration of colitis and reduced intestinal cytokine production. In LPS-activated murine macrophages, ethyl pyruvate decreased expression of IL-12 p40 and NO production but did not affect IL-10 levels. Ethyl pyruvate did not inhibit nuclear translocation of NF-κB family members but attenuated NF-κB DNA binding. Additionally, ethyl pyruvate induced HO-1 mRNA and protein expression and HO-1 promoter activation. Moreover, ethyl pyruvate prevented nuclear-to-cytoplasmic translocation of HMGB1. In conclusion, the HMGB1/RAGE pathway has pathophysiologic and diagnostic significance in experimental colitis. Ethyl pyruvate and other strategies to inhibit HMGB1 release and function represent promising interventions in chronic inflammatory diseases.

AB - Signals from stressed cells and the enteric microbiota activate macrophages and dendritic cells and mediate intestinal inflammation. HMGB1 serves as an immunogenic stimuli causing release of inflammatory cytokines by myeloid cells. Ethyl pyruvate inhibits secretion of HMGB1 and improves survival in models of endotoxemia and hemorrhagic shock. We reasoned that ethyl pyruvate may be protective in colitis, which involves similar inflammatory pathways. In IL-10-/- mice with established chronic colitis, ethyl pyruvate administration ameliorated colitis and reduced intestinal cytokine production. IL-10-/- mice demonstrated increased intestinal HMGB1 expression and decreased expression of RAGE compared with wild-type mice. Fecal HMGB1 levels were decreased in ethyl pyruvate-treated mice. Furthermore, ethyl pyruvate induced HO-1 expression in intestinal tissue. In TNBS-induced colitis, intrarectal administration of ethyl pyruvate resulted in amelioration of colitis and reduced intestinal cytokine production. In LPS-activated murine macrophages, ethyl pyruvate decreased expression of IL-12 p40 and NO production but did not affect IL-10 levels. Ethyl pyruvate did not inhibit nuclear translocation of NF-κB family members but attenuated NF-κB DNA binding. Additionally, ethyl pyruvate induced HO-1 mRNA and protein expression and HO-1 promoter activation. Moreover, ethyl pyruvate prevented nuclear-to-cytoplasmic translocation of HMGB1. In conclusion, the HMGB1/RAGE pathway has pathophysiologic and diagnostic significance in experimental colitis. Ethyl pyruvate and other strategies to inhibit HMGB1 release and function represent promising interventions in chronic inflammatory diseases.

KW - Inflammation

KW - Inflammatory bowel disease

KW - Innate immunity

UR - http://www.scopus.com/inward/record.url?scp=70149106605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149106605&partnerID=8YFLogxK

U2 - 10.1189/jlb.1008662

DO - 10.1189/jlb.1008662

M3 - Article

VL - 86

SP - 633

EP - 643

JO - Journal of Leukocyte Biology

JF - Journal of Leukocyte Biology

SN - 0741-5400

IS - 3

ER -